Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Adamis Pharmaceuticals Corporation | ADMP | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.775063 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.775063 | 0.775063 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.75 - 8.28 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.775063 | USD |
Adamis Pharmaceuticals Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 7.25M | - | - | - | -461.81 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Adamis Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 9/08/2023 | 15:50 | Edgar (US Regulatory) | Form 8-K - Current report |
| 9/07/2023 | 11:00 | GlobeNewswire Inc. | Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals.. |
| 9/01/2023 | 15:45 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/29/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/21/2023 | 16:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/21/2023 | 08:15 | GlobeNewswire Inc. | Adamis Pharmaceuticals Reports Second Quarter 2023 Financial.. |
| 8/14/2023 | 15:38 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 8/10/2023 | 15:03 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial.. |
| 8/04/2023 | 12:43 | GlobeNewswire Inc. | Adamis Pharmaceuticals Announces Closing of $8.0 Million.. |
| 8/03/2023 | 15:59 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/03/2023 | 15:55 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 8/02/2023 | 07:30 | GlobeNewswire Inc. | Adamis Pharmaceuticals Announces Pricing of $8.0 Million.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADMP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 7.063 | 8.28 | 0.75 | 2.66 | 1,819,100 | -6.29 | -89.03% |
| 3 Years | 49.812 | 103.60 | 0.75 | 53.38 | 2,761,920 | -49.04 | -98.44% |
| 5 Years | 134.40 | 171.50 | 0.75 | 66.66 | 3,544,043 | -133.62 | -99.42% |
Adamis Pharmaceuticals Description
| Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |
